Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

Completed · Phase 3

Conditions studied: Primary Sclerosing Cholangitis

In brief

Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.

Key facts

Study ID

NCT01802073

Run by

Stanford University

People needed

34

Starts

2012-01-01

Expected to finish

2015-08-01

Last updated by the study team

2018-09-21

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• PSC Diagnosis: Liver biopsy and/or imaging (MRCP, ERCP, CT, or US
• Colonoscopy within 1 year or starting of study
• 2 groups:
• IBD (Inflammatory bowel disease) and PSC: details of extent and type of IBD
• No IBD and PSC, but positive p-ANCA or ASCA serologies indicating possible IBD.

You may not qualify if…

• Allergy to Vancomycin
• PSC not associated with IBD or NO positive IBD antibodies (p-ANCA [anti- neutrophil cytoplasmic antibody] or ASCA [anti-Saccharomyces cerevisiae antibody])
• Cholangiocarcinoma
• On oral or topical (enemas or suppositories) corticosteroids,topical mesalamine, or biologics (infliximab, adalimumab, certolizumab).

Where it is running

• Stanford University Medical Center — Palo Alto, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.